Johnson & Johnson (NYSE: JNJ) and Pfizer (NYSE: PFE) both sell prescription medicines, offering investors different ways to own healthcare in 2026. Pfizer is adding to its pipeline through deals such as its November 2025 purchase of Metsera, a developer of obesity treatments. Both companies are also managing the loss of exclusivity on major products.
POLARIS INSIGHTS